Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them

Nat Commun. 2019 May 6;10(1):2073. doi: 10.1038/s41467-019-09819-1.

Abstract

Isolation of broadly neutralizing human monoclonal antibodies (HmAbs) targeting the E2 glycoprotein of Hepatitis C virus (HCV) has sparked hope for effective vaccine development. Nonetheless, escape mutations have been reported. Ideally, a potent vaccine should elicit HmAbs that target regions of E2 that are most difficult to escape. Here, aimed at addressing this challenge, we develop a predictive in-silico evolutionary model for E2 that identifies one such region, a specific antigenic domain, making it an attractive target for a robust antibody response. Specific broadly neutralizing HmAbs that appear difficult to escape from are also identified. By providing a framework for identifying vulnerable regions of E2 and for assessing the potency of specific antibodies, our results can aid the rational design of an effective prophylactic HCV vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology*
  • Antibodies, Neutralizing / immunology*
  • Antibodies, Viral / immunology*
  • Computer Simulation
  • Drug Design
  • Epitope Mapping / methods
  • Epitopes / genetics
  • Epitopes / immunology
  • Evolution, Molecular
  • Hepacivirus / genetics
  • Hepacivirus / immunology*
  • Hepatitis C / immunology*
  • Hepatitis C / prevention & control
  • Hepatitis C / virology
  • Humans
  • Models, Biological
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology*
  • Viral Hepatitis Vaccines / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Epitopes
  • Viral Envelope Proteins
  • Viral Hepatitis Vaccines
  • glycoprotein E2, Hepatitis C virus